fondaparinux
Sign in to saveFondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by Viatris. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories.
Research
2,357 papers- Fondaparinux Sodium: Recent Advances in the Management of Thrombosis.Journal of cardiovascular pharmacology and therapeutics · 2023
- Fondaparinux.Current pharmaceutical design · 2005
- Fondaparinux-associated heparin-induced thrombocytopenia.European journal of haematology · 2013
- Fondaparinux sodium.Drugs of today (Barcelona, Spain : 1998) · 2002
- Fondaparinux sodium.Drugs · 2002
via PubMed
Article
8 sectionsContents
- Medical uses
- Comparison to other agents
- Pharmacology
- Mechanism of action
- Chemistry
- Abbreviations
- References
- External links
Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by Viatris. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories.
==Medical uses== Clinically, it is used for the prevention of deep vein thrombosis in patients who have had orthopedic surgery as well as for the treatment of deep vein thrombosis and pulmonary embolism.